ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print June 28, 2006, 10.1183/09031936.06.00030206
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reichenberger, F.
Right arrow Articles by Ghofrani, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reichenberger, F.
Right arrow Articles by Ghofrani, H. A.
Eur Respir J 2006; 28:563-567
Copyright ©ERS Journals Ltd 2006

Sildenafil treatment for portopulmonary hypertension

F. Reichenberger1, R. Voswinckel1, E. Steveling1, B. Enke1, A. Kreckel1, H. Olschewski2, F. Grimminger1, W. Seeger1 and H. A. Ghofrani1

1 Pulmonary Vascular Diseases Unit, University of Giessen Lung Center, Dept of Internal Medicine, University Hospital Giessen, Giessen Germany. 2 Division of Chest Medicine, University Hospital Graz, Graz, Austria.

CORRESPONDENCE: F. Reichenberger, University of Giessen Lung Center, University Hospital Giessen, Klinikstrasse 36, 35392 Giessen, Germany. Fax: 49 6419942599. E-mail: Frank.Reichenberger{at}innere.med.uni-giessen.de

Keywords: Inhaled prostanoids, portopulmonary hypertension, pulmonary circulation, sildenafil

Received: February 28, 2006
Accepted June 15, 2006

Portopulmonary hypertension (POPH) is regarded as a subtype of pulmonary arterial hypertension (PAH); however, established PAH therapies have not been evaluated for this condition.

The current authors treated 14 patients (four male, 10 female; mean (range) age 55 (39–75) yrs) with moderate (n = 1) or severe (n = 13) POPH caused by alcoholic liver disease (n = 7), chronic viral hepatitis (n = 3), autoimmune hepatitis (n = 3), and hepatic manifestation of hereditary haemorrhagic teleangiectasia (n = 1) with oral sildenafil. Eight patients were newly started on pulmonary vasoactive treatment, while six patients were already on treatment with inhaled prostanoids (iloprost, n = 5; treprostinil, n = 1). During treatment with sildenafil, mean±SD 6-min walk distance increased from 312±111 m to 397±99 m after 3 months, and 407±97 m after 12 months. Mean±SD pro-brain natriuretic peptide levels decreased from 582±315 ng·mL-1 to 230±278 ng·mL-1, and to 189±274ng·mL-1 after 3 and 12 months, respectively. Two patients died after 1 and 2 months from liver failure and cardiac failure, respectively. There was a similar response to sildenafil treatment after 3 and 12 months in patients on monotherapy and those on combination therapy.

In conclusion, sildenafil might be effective in monotherapy and in combination therapy with inhaled prostanoids in portopulmonary hypertension, leading to significant improvement by 3 months and sustained response over 12 months.




This article has been cited by other articles:


Home page
Eur Respir JHome page
M. M. Hoeper, H. J. Seyfarth, G. Hoeffken, H. Wirtz, E. Spiekerkoetter, M. W. Pletz, T. Welte, and M. Halank
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Eur. Respir. J., December 1, 2007; 30(6): 1096 - 1102.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. A. Kass, H. C. Champion, and J. A. Beavo
Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation
Circ. Res., November 26, 2007; 101(11): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. M. Hoeper
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value
Eur. Respir. J., March 1, 2007; 29(3): 432 - 434.
[Full Text] [PDF]


Home page
Eur Respir JHome page
P. Deibert, H. Bremer, M. Roessle, A-K. Kurz-Schmieg, and W. Kreisel
PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension
Eur. Respir. J., January 1, 2007; 29(1): 220 - 221.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M. J. Krowka and K. L. Swanson
How should we treat portopulmonary hypertension?
Eur. Respir. J., September 1, 2006; 28(3): 466 - 467.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.